$BIIB up a monster 30% today. I was curious why, and it turned out their blockbuster Alzheimer's drug, aducanumab, which they discontinued studying in March, may actually work. Stock tanked 30%+ then. Now it's back. Very odd situation.https://www.statnews.com/2019/10/22/biogen-to-submit-aducanumab/ …
-
I don't think it's supposed to be merely symptomatic. It targets beta amyloid so it may plausibly slow down Alzheimer's. If it works, it's huge.
